Pediatric Neurology
Volume 42, Issue 6 , Pages 422-426 , June 2010

Prevalence and Risk Factors for Vitamin D Insufficiency Among Children With Epilepsy

  • Renée A. Shellhaas, MD, MS

      Affiliations

    • Division of Pediatric Neurology, Department of Pediatrics and Communicable Diseases, Ann Arbor, Michigan
    • Corresponding Author InformationCommunications should be addressed to: Dr. Shellhaas; L3215 Women's Hospital; 1500 E. Medical Center Drive, SPC 5203; Ann Arbor, MI 48109-5203.
    • ,
  • Amanda K. Barks

      Affiliations

    • College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, Michigan
    • ,
  • Sucheta M. Joshi, MD, MS

      Affiliations

    • Division of Pediatric Neurology, Department of Pediatrics and Communicable Diseases, Ann Arbor, Michigan

Received 28 December 2009 ,Accepted 1 March 2010.

References 

  1. Offer Mann G, Pinto V, Kruse R. Antiepileptic drugs and vitamin D supplementation. Epilepsia. 1979;20:3–15
  2. Sheath RD, Gilda BE, Hermann BP. Pathological fractures in epilepsy. Epilepsy Behav. 2006;9:601–605
  3. Sovereign PC, Webb DJ, Weil JG, Van STA TP, Egbert's ACG. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology. 2006;66:1318–1324
  4. Estraguard P. Epilepsy, osteoporosis and fracture risk: a meta-analysis. Acta Neurol Scand. 2005;112:277–286
  5. Altay E, Serdaroğlu A, Tümer L, Gücüyener K, Hasanoğlu A. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab. 2000;13:933–939
  6. Guo C-Y, Ronene GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia. 2001;42:1141–1147
  7. Bergqvist AGC, Schall JI, Stallings VA. Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia. 2007;48:66–71
  8. el-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone. 2008;43:149–155
  9. Mikati MA, Dib B, Yamout B, Sawaya R, Rahi AC, el-Hajj Fuleihan G [Fuleihan Gel-H]. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology. 2006;67:2005–2014
  10. Nicolaidou P, Georgouli H, Kotsalis H, et al. Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J Child Neurol. 2006;21:205–209
  11. Sheth RD, Binkley N, Hermann BP. Progressive bone deficit in epilepsy. Neurology. 2008;70:170–176
  12. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127:256–262
  13. Tekgul H, Dizdarer G, Demir N, Ozturk C, Tutuncuoglu S. Antiepileptic drug-induced osteopenia in ambulatory epileptic children receiving a standard vitamin D3 supplement. J Pediatr Endocrinol Metab. 2005;18:585–588
  14. Tekgul H, Serdaroğlu G, Huseyinov A, Gökben S. Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy. J Child Neurol. 2006;21:411–414
  15. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73–78
  16. Rovner AJ, O'Brien KO. Hypovitaminosis D among healthy children in the United States: a review of the current evidence. Arch Pediatr Adolesc Med. 2008;162:513–519
  17. Saintonge S, Bang H, Gerber LM. Implications of a new definition of vitamin D deficiency in a multiracial US adolescent population: The National Health and Nutrition Examination Survey III. Pediatrics. 2009;123:797–803
  18. Wagner CL, Greer FR American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents [Erratum in: Pediatrics 2009;123:197]. Pediatrics. 2008;122:1142–1152
  19. Reis JP, von Muhlen D, Miller ER, Michos ED, Appel LJ. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics. 2009;124:e371–e379
  20. Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology. 2009;73:658–664
  21. Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics. 2009;124:e362–e370
  22. Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol. 2006;35:177–181
  23. Cansu A, Yesilkaya E, Serdaroğlu A, et al. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol. 2008;39:266–271
  24. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006;47:510–515
  25. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988;67:373–378
  26. Svoren BM, Volkening LK, Wood JR, Laffel LMB. Significant vitamin D deficiency in youth with type I diabetes mellitus. J Pediatr. 2009;154:132–134
  27. Wright TB, Shults J, Leonard MB, Zemel BS, Burnham JM. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr. 2009;155:260–265
  28. Volpe SL, Schall JI, Gallagher PR, Stallings VA, Bergqvist AGC. Nutrient intake of children with intractable epilepsy compared with healthy children. J Am Diet Assoc. 2007;107:1014–1018
  29. Yetley EA. Assessing the vitamin D status of the US population. Am J Clin Nutr. 2008;88:558S–564S

PII: S0887-8994(10)00101-3

doi: 10.1016/j.pediatrneurol.2010.03.004

Pediatric Neurology
Volume 42, Issue 6 , Pages 422-426 , June 2010

Article Tools